~~<i id='06B073DE61'><strike id='06B073DE61'><tt id='06B073DE61'><pre id='06B073DE61'></pre></tt></strike></i>~~

Home» leisure time» explore

explore

author：explore 2025-10-02 03:26:10 Page View：4275

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Do masks work? RCTs can't tell us
Next article： In age of alternative facts, a scholarly course on calling out crap

explore

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

Addiction experts warn against a second 'war on drugs'

STAT'sLevFacher(left)spokewiththreeaddictionexperts—(fromleft)BraunzCourtney,KeithHumphreys,andAyesh

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Why drug prescriptions should include diagnoses

AdobeTheCovid-19pandemicisteachingusmanytragiclessonsalongwithsomeinstructiveones,liketheimportanceo